|
|
Article: Nuvo Research responds to increased trading activity.
- Article from:
- Medical Letter on the CDC & FDA
- Article date:
- November 15, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Nuvo Research Inc. (TSX:NRI), today responded to a request from the Investment Industry Regulatory Organization of Canada (IIROC) on behalf of the Toronto Stock Exchange following recent trading activity of Nuvo shares (see also Nuvo Research Inc.).
While it is Nuvo's policy not to comment on market rumours or speculation, at the request of IIROC, Nuvo is confirming that, as previously disclosed, it anticipates receiving a decision from the United States Food and Drug Administration (FDA) on or about November 4, 2009 pertaining to the approvability of the Company's lead drug Pennsaid[R].
...